[]

Find Dermatology Drugs in Phase I Clinical Development in ISRAEL

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : BiomX is developing BX001, a topically administered gel comprised of a cocktail of naturally occurring phage targeting Cutibacterium acnes (C. acnes) used to modify the appearance of acne prone skin.

                          Product Name : BX001

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 20, 2020

                          Lead Product(s) : BX001

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank